Publicaciones en las que colabora con JUAN TAMARGO MENÉNDEZ (85)

2024

  1. Coexistent HCN4 and GATA5 Rare Variants and Atrial Fibrillation in a Large Spanish Family

    Canadian Journal of Cardiology, Vol. 40, Núm. 7, pp. 1270-1280

  2. Drug-induced atrial fibrillation. A narrative review of a forgotten adverse effect

    Pharmacological Research, Vol. 200

  3. News in cardiovascular pharmacotherapy from the ACC.24 Meeting

    European heart journal. Cardiovascular pharmacotherapy

  4. Reply to Benndorff and DiFrancesco: Reliable human HCN4 single-channel recordings using the cell-attached configuration in expression systems

    Proceedings of the National Academy of Sciences of the United States of America

2023

  1. A Cantú syndrome mutation produces dual effects on KATP channels by disrupting ankyrin B regulation

    The Journal of general physiology, Vol. 155, Núm. 1

  2. A gain-of-function HCN4 mutant in the HCN domain is responsible for inappropriate sinus tachycardia in a Spanish family

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 120

  3. Sex and gender differences in the treatment of arterial hypertension

    Expert Review of Clinical Pharmacology, Vol. 16, Núm. 4, pp. 329-347

2022

  1. Cancer Chemotherapy-Induced Sinus Bradycardia: A Narrative Review of a Forgotten Adverse Effect of Cardiotoxicity

    Drug Safety, Vol. 45, Núm. 2, pp. 101-126

  2. Empagliflozin and Dapagliflozin Increase Na+ and Inward Rectifier K+ Current Densities in Human Cardiomyocytes Derived from Induced Pluripotent Stem Cells (hiPSC-CMs)

    Cells, Vol. 11, Núm. 23

  3. Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline

    Expert Opinion on Investigational Drugs, Vol. 31, Núm. 10, pp. 1027-1052

  4. Regulation of cardiac ion channels by transcription factors: Looking for new opportunities of druggable targets for the treatment of arrhythmias

    Biochemical Pharmacology, Vol. 204

  5. Sex-related differences in the pharmacological treatment of heart failure

    Pharmacology and Therapeutics, Vol. 229

  6. Tbx5 variants disrupt Nav1.5 function differently in patients diagnosed with Brugada or Long QT Syndrome

    Cardiovascular research, Vol. 118, Núm. 4, pp. 1046-1060

2021

  1. The pharmacotherapeutic management of hyperkalemia in patients with cardiovascular disease

    Expert Opinion on Pharmacotherapy, Vol. 22, Núm. 10, pp. 1319-1341

  2. Zfhx3 transcription factor represses the expression of SCN5A gene and decreases sodium current density (Ina)

    International Journal of Molecular Sciences, Vol. 22, Núm. 23

2017

  1. Propiverina

    Universidad Complutense de Madrid

  2. Tbx20 controls the expression of the KCNH2 gene and of hERG channels

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 114, Núm. 3, pp. E416-E425

2016

  1. Cardiac electrical defects in progeroid mice and Hutchinson-Gilford progeria syndrome patients with nuclear lamina alterations

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 113, Núm. 46, pp. E7250-E7259

  2. Nav1.5 N-terminal domain binding to α1-syntrophin increases membrane density of human Kir2.1, Kir2.2 and Nav1.5 channels

    Cardiovascular Research, Vol. 110, Núm. 2, pp. 279-290

  3. Pitx2c increases in atrial myocytes from chronic atrial fibrillation patients enhancing IKs and decreasing ICa,L

    Cardiovascular Research, Vol. 109, Núm. 3, pp. 431-441